ABSTRACT
Fifty-two combinations of nitrofurantoin were developed to assess the effect of dosage form type, particle size, diluent, and process on in vitro availability. With the official procedure and conditions, dissolution rates fell in a 66-fold range. Statistical analysis of the dissolution rates indicated no significant differences as a result of particle size, processing method, or compression force. The diluent choice and dosage form type significantly influenced the dissolution rate. Based on in vitro screening, six formulations presenting a broad range of dissolution rates were selected for further study relating to human bioavailability and bioequivalence.
Subject(s)
Nitrofurantoin/metabolism , Capsules , Drug Compounding , Excipients , Hardness , Nitrofurantoin/administration & dosage , Particle Size , Solubility , Tablets , Therapeutic EquivalencyABSTRACT
Based on preliminary in vitro evaluation, six formulations presenting a broad range of dissolution rates were selected for bioequivalency determination in a randomized complete block crossover. In vitro-in vivo correlations were developed relating cumulative percent dissolved to cumulative percent excreted. These correlations appear to be useful for comparing different formulations as well as different batches of the same formulation.
